Taro Pharmaceutical Industries Ltd - Company Profile
Powered by 
All the data and insights you need on Taro Pharmaceutical Industries Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Taro Pharmaceutical Industries Ltd Strategy Report
- Understand Taro Pharmaceutical Industries Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Taro Pharmaceutical Industries Ltd (Taro) discovers, develops and markets healthcare products. The company manufactures prescription drugs, non-prescription drugs and active pharmaceutical ingredients (APIs). It develops pharmaceutical products in semi-solids formulations, such as ointments and creams and other dosage forms including liquids, capsules and tablets. Taro develops products in dermatological and topical, neuropsychiatric, anti-inflammatory and cardiovascular areas. The company sells and distributes its product to healthcare institutions, drug store chains, and private pharmacies. It has presence in Israel, the US, Canada and other countries. The company markets over 200 pharmaceutical products in more than 20 countries worldwide. Taro is headquartered in Haifa Bay, Israel.
Headquarters
Israel
Address
14 Hakitor Street, Po Box 10347, Haifa, 2624761
Website
www.taro.com
Telephone
972 4 8475700
No of Employees
1,554
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TARO (NYSE)
Revenue (2022)
$573.0M
2.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-56.3%
(2022 vs 2021)
Market Cap*
$1.6B
Net Profit Margin (2022)
XYZ
-57.2%
(2022 vs 2021)
* As of and is in US$
Taro Pharmaceutical Industries Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product Categories: | Anafranil |
| Cardiovascular Products | Aldara |
| Antibiotics | Claritin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In June, the company launched Bee Rx in Canada. |
| 2022 | Contracts/Agreements | In February, the company completed the acquisition of Alchemee, a proactive company. |
| 2020 | New Products/Services | In September, the company launched a new specialty generic Deferiprone Tablets in the US for the treatment of patients with thalassemia syndromes. |
Competitor Comparison
| Key Parameters | Taro Pharmaceutical Industries Ltd | Merck & Co Inc | Pfizer Inc | Novartis AG | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | Israel | United States of America | United States of America | Switzerland | United States of America |
| City | Haifa | Kenilworth | New York | Basel | Princeton |
| State/Province | - | New Jersey | New York | - | New Jersey |
| No. of Employees | 1,554 | 72,000 | 88,000 | 76,057 | 34,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dilip Shanghvi | Chairman | Executive Board | 2013 | 67 |
| Uday Baldota | Chief Executive Officer; Director | Executive Board | 2017 | 53 |
| William J. Coote | Vice President; Chief Accounting Officer; Chief Financial Officer | Senior Management | 2021 | 68 |
| Abhay Gandhi | Vice Chairman | Executive Board | 2017 | 58 |
| Moshe Gavrilov | Head - Commercial Israel and Rest of World; Vice President | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer